CardioBreak: Lariat LAA Questions; Synthetic Stem Cells; Alcohol Risk – MedPage Today
|
CardioBreak: Lariat LAA Questions; Synthetic Stem Cells; Alcohol Risk
MedPage Today STAT News took a long look at the Lariat device used off-label for left atrial appendage closure and questioned whether it should have gone through a different regulatory approval process at the FDA. Following the FDA’s approval of a cardiovascular … |
Health Essentials from Cleveland Clinic (blog) |
Can Gene Therapy Prevent Blindness? What You Need to Know
Health Essentials from Cleveland Clinic (blog) “We will see significant advances in gene transfer therapy, stem cell therapies and drug therapies for hereditary retinal diseases in the coming decades.” To prepare for these emerging therapies, Cleveland Clinic eye experts work with genetic … |
|
Research turns stem cells into skin grafts
Daily Mining Gazette Provided photo An MTU research project has developed a way to produce natural skin grafts from a person’s own stem cells. HOUGHTON — For burn victims and people with other injuries which cause damage to skin, skin grafts are an important part of … |
Investopedia |
Amgen, Immatics Launch Up-to-$1B+ Cancer Immunotherapy Alliance
Genetic Engineering & Biotechnology News Amgen will partner with Immatics Biotechnologies to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, through a collaboration the companies said today could generate more than $1 billion for Immatics. Amgen (AMGN), Immatics Biotechnologics To Collaborate On Novel Bispecific Cancer Immunotherapies DevelopmentStreetInsider.com Amgen, Immatics In Cancer Drug Partnership (AMGN)Investopedia Amgen Invests $30M In Immatics, Up To $1 Billion In Future PaymentssocalTech.com |
Next Big Future |
Interference: A CRISPR Patent Dispute Roadmap
Bio-IT World January 9, 2017 | Emmanuelle Charpentier and Jennifer Doudna have become world renowned for their discoveries and development involving CRISPR/Cas9, a gene-editing technology that has been called “one of the most important genetic inventions of … CRISPR could make designer babies and help with many diseases and moreNext Big Future |
|
TissueGene to Highlight Invossa™, the World’s First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis, at …
Yahoo Finance Mr. Lee will introduce TissueGene’s Invossa™, the world’s first cell and gene therapy for degenerative arthritis. Invossa™ is a first-in-class osteoarthritis drug designed to conveniently and effectively treat osteoarthritis of the knee through a … |
|
TissueGene to Highlight Invossa™, the World’s First Cell-Mediated Gene Therapy for Degenerative
PR Newswire (press release) Mr. Lee will introduce TissueGene’s Invossa™, the world’s first cell and gene therapy for degenerative arthritis. Invossa™ is a first-in-class osteoarthritis drug designed to conveniently and effectively treat osteoarthritis of the knee through a … |